These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 27734073

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D, Ditch K, Medeiros K, Doyno C, Fong JJ.
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [Abstract] [Full Text] [Related]

  • 24. Assessment of patients post reversal with idarucizumab.
    Raco V, Ahuja T, Green D.
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.
    Stecher A, Vene N, Mavri A, Mijovski MB, Krevel B, Gradišek P.
    Eur J Anaesthesiol; 2017 Jun; 34(6):400-402. PubMed ID: 28459790
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Idarucizumab for Dabigatran Reversal Guideline.
    Reardon DP, Owusu K.
    Crit Pathw Cardiol; 2016 Jun; 15(2):33-5. PubMed ID: 27183250
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z.
    Orv Hetil; 2016 Mar 20; 157(12):443-50. PubMed ID: 26971644
    [Abstract] [Full Text] [Related]

  • 32. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L, Barabás É, Bodócs I, Szántó Z, Herr G, Bencsik G, Pál L, Borbola J.
    Orv Hetil; 2017 Mar 20; 158(10):387-392. PubMed ID: 28270004
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Successful dabigatran reversal after subdural hemorrhage using idarucizumab in a mobile stroke unit: A case report.
    Thirunavukkarasu S, Kalashyan H, Jickling G, Jeerakathil TJ, Jayaprakash HK, Buck BH, Shuaib A, Butcher K.
    Medicine (Baltimore); 2020 May 22; 99(21):e20200. PubMed ID: 32481289
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N, Morrill AM, Willett KC.
    Am J Ther; 2018 May 22; 25(3):e333-e338. PubMed ID: 27175894
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M, Spronk HM, Rossaint R, Stoppe C, van Ryn J, Ten Cate H, Grottke O.
    Thromb Haemost; 2017 Jun 28; 117(7):1370-1378. PubMed ID: 28424818
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.